Weave Now Integrates with Neo
Appointment Reminders and Confirmation Writebacks: Weave sends automated appointment reminders to clients to help keep schedules full and writes back their confirmation status in both systems.
Automated Data Sync: Keeps client contact and appointment information current in Weave with regular updates from the Neo database.
Phones and Call Pop: Displays the client's profile when they call into the practice, enabling staff to know more about clients when they call and deliver more personalized communications.
Vaccination Reminders: Automated text reminders help clients keep their pet's vaccinations up-to-date.
Reviews: Weave Reviews makes it easy for an office to collect and monitor reviews on Google and Facebook.
Missed-call Text: Never miss an opportunity with missed-call text messages whether you're away or busy with another client.
Text Writebacks: Vet Text Writebacks will enable office staff to easily transfer a text message to the PMS so that no important information in their care is lost and proper care is given with the doctors.
Weave empowers veterinary practices to attract, engage, and retain clients while streamlining operations and reducing administrative burdens. By providing intuitive tools that enhance communication and efficiency, Weave enables providers to focus on delivering exceptional care while building successful, patient-centered businesses. By streamlining payment processes with text-to-pay, online payments, and flexible options like payment plans, Weave accelerates collections, reduces write-offs, and improves practice profitability. To learn more about Weave's integration with IDEXX's Neo, visit getweave.com/integration/neo.
About Weave
Weave is the leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire patient journey. Weave's software solutions transform how healthcare practices attract, communicate with, and engage patients and clients to grow their business. Weave seamlessly integrates billing and payment requests into communication workflows, streamlining payment timelines, reducing accounts receivable, and supporting practice profitability. In the past year, Weave has been named an Inc. Power Partner, a G2 leader in Patient Relationship Management software and a Top 50 Product for Small Business. To learn more, visit getweave.com/newsroom/.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Take 2 R&S LLC Positioned as Industry Leader as California Mandates Safety Advisors in Film & TV Tax Credit Program
LOS ANGELES--(BUSINESS WIRE)--With the California Film Commission's recent enhancement to its Film & Television Tax Credit Program, mandating Safety Advisors on qualifying productions, Take 2 R&S LLC is proud to announce its readiness to meet this critical industry need with unparalleled expertise, infrastructure, and talent. Effective immediately, all productions receiving the California Tax Incentive must now retain Safety Advisors to oversee compliance with set safety protocols. This move—designed to elevate health and safety standards—mirrors longstanding studio-level expectations and aims to protect cast and crew across all production environments. Take 2 R&S LLC, a trusted partner in risk and safety management, is the only firm in California uniquely positioned to fulfill this mandate at scale. The company offers a turnkey solution modeled after major studio safety departments, combining decades of hands-on experience with a robust roster of certified professionals. 'This new requirement aligns perfectly with what we've been doing for years,' said Michael Tamburro, Founder of Take 2 R&S LLC. 'Our team doesn't just check boxes—we integrate safety into the culture of each production. We've built a structure that mirrors the major studios and can scale immediately to support both indie and large-scale projects.' Take 2's Safety Advisors are more than compliance officers—they are production veterans with specialized training in film and television safety standards, OSHA protocols, and incident prevention. The company supports clients with: On-set Safety Advisors tailored to each project's scale and complexity Studio-style infrastructure including incident reporting systems, site inspections, and daily safety briefings Close collaboration with producers, line staff, and labor unions to meet and exceed state mandates As Hollywood adapts to this evolving regulatory landscape, Take 2 R&S LLC is already delivering proactive, trusted solutions—ensuring productions remain eligible for tax incentives while protecting the people who bring stories to life.
Yahoo
42 minutes ago
- Yahoo
The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now
Key Points American Express only issues its cards to lower-risk consumers. As both a card issuer and a bank, it's well-insulated from interest rate swings. Its stock is still reasonably valued relative to its growth potential. 10 stocks we like better than American Express › Many investors follow Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) $293.8 billion portfolio because those stocks were approved by Warren Buffett himself. Even though Buffett plans to step down as Berkshire's chief executive officer this year, his successor, Greg Abel, probably won't dramatically shake up those top holdings. One of those top investments is American Express (NYSE: AXP), which accounts for 15.9% of Berkshire's portfolio and is the company's second largest holding after Apple (NASDAQ: AAPL). Buffett initially accumulated shares of American Express in 1964 through a partnership before his full takeover of Berkshire Hathaway in 1965, and he significantly increased Berkshire's position in the company in 1991. Today, Berkshire owns 21.6% of the entire company. Berkshire hasn't bought or sold any shares of American Express since 2012. Let's see why Buffett considered it to be such a reliable long-term investment -- and why it's a great place to park a fresh $1,000 investment, even as the market hovers near its all-time highs. It's an exclusive club for higher-income consumers American Express is often considered a credit card company like Visa (NYSE: V) and Mastercard (NYSE: MA), but it operates a completely different business model. Visa and Mastercard don't issue any cards or run their own banks. They only partner with banks and other financial institutions to issue co-branded cards and handle those accounts. Visa and Mastercard only generate revenue by charging merchants "swipe fees" for every transaction that runs through their card-processing networks. American Express is both a card issuer and a bank. Since it needs to support its own cards with its own balance sheet, it only offers those cards to lower-risk, higher-income consumers. That exclusivity limits its growth, but it also reduces its credit risk and boosts its appeal as a status symbol. That's why Buffett said you "can't create another American Express" in a Bloomberg interview in late 2022, and why he repeatedly praised its wide competitive moat. At the end of 2024, only 0.8% of American Express' consumer and small business loans were delinquent by more than 30 days, compared to a ratio of 1% at the end of 2023. It also only allocated 8% of its total revenue (net of interest expense) to its credit loss provisions in 2024. It's well-insulated from inflation and interest rate swings Since American Express is both a card issuer and a bank, it's better insulated from inflation and interest rate swings than Visa and Mastercard. Rising rates can reduce the swipe fees at all three companies as consumers curb spending. However, higher rates also boost the net interest income of American Express' banking segment by attracting more deposits and collecting higher interest payments on its loans. That balance makes it a good all-weather stock to hold, regardless of where interest rates go in the future. Stable growth rates at a reasonable valuation From 2014 to 2024, American Express' revenue (net of interest expense) and diluted earnings per share (EPS) grew at a compound annual growth rate (CAGR) of 7% and 10%, respectively. It also bought back nearly a third of its shares during the past 10 years, and it's paid continuous dividends for nearly five decades. It achieved that steady growth even as the pandemic, inflation, rising interest rates, geopolitical conflicts, and other macro headwinds rattled the global economy. From 2024 to 2027, analysts expect its revenue and diluted EPS to grow at CAGRs of 8% and 12%, respectively. That growth should be driven by higher spending among affluent customers (especially for travel and leisure), the rollout of more travel-related perks, higher fee-based revenue from its premium cards, and its overseas expansion. It's cheap relative to its growth potential American Express' stock has already gained about 290% during the past decade, but it still looks like a bargain at 20 times next year's earnings. For reference, Visa and Mastercard trade at 28 times and 35 times next year's earnings, respectively. American Express won't ever be an exciting growth play, but it's a great stock to buy, hold, and forget. Do the experts think American Express is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did American Express make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 American Express is an advertising partner of Motley Fool Money. Leo Sun has positions in Apple and Berkshire Hathaway. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Mastercard, and Visa. The Motley Fool has a disclosure policy. The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman Sachs analyst Asad Haider maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $56.00 price target, basing the rating on the company's current market position. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Haider stated that Bristol-Myers Squibb Company (NYSE:BMY) is anticipated to release mixed results for the upcoming quarter. While foreign exchange rates may have some positive impact on the earnings, potential negative effects from recent deals not fully accounted for in current earnings projections, and challenges at the product level are cause for concern. The analyst further said that Bristol-Myers Squibb Company's (NYSE:BMY) stock has remained stable within a narrow range despite it trading at a lower multiple compared to its peers and prior strong quarterly results. He reasoned that this stability is partially because of investors anticipating significant clinical trial outcomes, especially the Phase-3 ADEPT-2 trial for Cobenfy in Alzheimer's psychosis. The Hold rating thus suggests the need for clarity regarding these clinical developments as they may prove critical for future stock movement. Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
